SGNTUC-029 (MOUNTAINEER-03): An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer

Objective

Clinical Trial Details

Principal Investigator(s)

Heidi McKean, MD

Clinical Trial Categories

• Cancer
• Colorectal Cancer

Contact

Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org